HIV IN PATIENTS AND ANIMALS--CELL MEDIATED IMMUNITY AND VIRAL ISOLATION

我们继续与约翰·霍普金斯医学中心合作研究5 艾滋病毒骨髓移植研究中新登记的患者。序贯 以前从这些艾滋病患者身上分离的PBL上进行了病毒分离 和骨髓移植后。对患者的细胞进行培养 用正常的人类原始细胞培养4周，每周取样并检测HIV 抗原。以下数据汇总了截至1990年11月的结果， 表明病毒有减少的趋势 移植。该项目暂时停止，以进行重新评估和 将由Hana Golding博士在DNA病毒实验室继续进行。 恒河猴免疫后抗体和抗原状态的研究 1987年，随着活的HIV-1病毒继续显示没有检测到抗原， 而抗体在两种血清阳性的动物中持续存在，尽管抗体水平较低 级别。1988年9月接种的一组恒河猴也被跟踪 在本财年期间，结果表明猴子体内注射了gp160 重组牛痘疫苗对IIIB和RF病毒，随后是2个加强剂 纯化的gp160在95周内仍为阳性。一项随访研究 目的是评估接种IIIB-重组痘苗病毒和 使用纯化的gp160在2个月和8个月内提高2次，间隔不同于 与第一个实验一起使用时，将复制或最大化 之前看到的反应。妊娠5个月前的血清评价 结果表明，重组牛痘疫苗的初始接种可诱导 比最初接种纯化的gp160有更好的抗体应答。 这些动物的连续出血正在等待分析。 另一项研究测试了一种新的IIIB gp160重组体与用于 以前的研究，发现筛查时6个月内没有抗体反应 在标准的酶联免疫吸附试验上。用纯化的gp160酶联免疫吸附试验进行后续筛选 以及针对IIIB、MN、SF2的V3多肽抗体的ELISA特异性 和RF菌株，表明在一些动物中有低水平的反应 两组均在4个月前完成。

We continued collaboration with Johns Hopkins Medical Center studying 5 new patients enrolled in the HIV bone marrow transplant study. Sequential virus isolations were done on PBL isolated from these AIDS patients before and after bone marrow transplantation. The patients cells were cultured with normal human blast cells for 4 weeks, sampled weekly & tested for HIV antigen. The following data summarizes the results through 11/90, indicating that there is a trend towards virus reduction after transplantation. The project was temporarily halted for reevaluation and will be continued by Dr.Hana Golding in the Lab of DNA viruses. Studies of the antibody and antigen status of Rhesus monkeys inoculated in 1987 with live HIV-1 virus continued to reveal no antigen being detected, while antibody persisted in the 2 seropositive animals, though at lower levels. A group of Rhesus inoculated in Sept 1988 were also followed during this FY and results indicated that monkeys primed with a gp160 recombinant vaccinia to IIIB and RF viruses followed by 2 boosters with purified gp160 remained seropositive through 95 weeks. A followup study designed to evaluate whether inoculation of IIIB-recombinant vaccinia and 2 boosts with purified gp160 at 2 & 8 months, a different interval than used with the first experiment would either reproduce or maximize the response seen previously. Evaluation of sera through the 5th month indicated that initial inoculation with the vaccinia recombinant induced a better antibody response than initial inoculation with purified gp160. Sequential bleeds from these animals are awaiting analysis. Another study tested a new IIIB gp160 recombinant compared to that used in previous studies and found no antibody response in 6 months when screened on a standard ELISA. Subsequent screening using a purified gp160 ELISA as well as ELISA's specific for antibodies to V3 peptides of IIIB, MN, SF2 and RF strains, indicated low level responses in some of the animals in both groups by the 4th month.